APA

Heath E. I., Heilbrun L. K., Li J., Vaishampayan U., Harper F., Pemberton P. & Sarkar F. H. (20110714). A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. : American journal of translational research.

Chicago

Heath Elisabeth I, Heilbrun Lance K, Li Jing, Vaishampayan Ulka, Harper Felicity, Pemberton Pam and Sarkar Fazlul H. 20110714. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. : American journal of translational research.

Harvard

Heath E. I., Heilbrun L. K., Li J., Vaishampayan U., Harper F., Pemberton P. and Sarkar F. H. (20110714). A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. : American journal of translational research.

MLA

Heath Elisabeth I, Heilbrun Lance K, Li Jing, Vaishampayan Ulka, Harper Felicity, Pemberton Pam and Sarkar Fazlul H. A phase I dose-escalation study of oral BR-DIM (BioResponse 3,3'- Diindolylmethane) in castrate-resistant, non-metastatic prostate cancer. : American journal of translational research. 20110714.